A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies
暂无分享,去创建一个
S. Kesari | D. Hong | D. Blum | D. Piccioni | S. Fu | R. Lukas | D. Aregawi | N. Poola | Hongtao Liu | Yi Zhang | Kenichiro Yamaguchi | K. Whicher | Yu-Luan Chen | John Eddy
[1] Y. Oji,et al. Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review , 2020, Frontiers in Oncology.
[2] R. Rabadán,et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma , 2019, Nature Medicine.
[3] J. Sakamoto,et al. A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma , 2018, Cancer Immunology, Immunotherapy.
[4] Man Xiao,et al. Phase I/II clinical trial of a Wilms’ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer , 2018, Cancer Immunology, Immunotherapy.
[5] David A Scheinberg,et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. , 2018, Blood advances.
[6] Yusuke Nakamura,et al. WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia , 2018, Experimental Hematology & Oncology.
[7] M. Zauderer,et al. A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma , 2017, Clinical Cancer Research.
[8] K. Hongo,et al. Clinical effect and immunological response in patients with advanced malignant glioma treated with WT1-pulsed dendritic cell-based immunotherapy: A report of two cases , 2017 .
[9] A. Rhodes,et al. Expression of WT1 and PAX8 in the epithelial tumours of Malaysian women with ovarian cancer , 2017, British journal of biomedical science.
[10] Benjamin M. Ellingson,et al. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials , 2017, Neurotherapeutics.
[11] R. Colen,et al. Cancer Imaging in Immunotherapy. , 2017, Advances in experimental medicine and biology.
[12] S. Partlová,et al. Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines , 2016, Oncotarget.
[13] T. Yoshimine,et al. Functional Roles of Wilms’ Tumor 1 (WT1) in Malignant Brain Tumors , 2016 .
[14] A. Carella,et al. Wilms’ Tumor Gene (WT1) Expression and Minimal Residual Disease in Acute Myeloid Leukemia , 2016 .
[15] Naoya Hashimoto,et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.
[16] K. Hongo,et al. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma. , 2015, Journal of neurosurgery.
[17] Jingting Jiang,et al. Wilms’ tumor 1 enhances Cisplatin‐resistance of advanced NSCLC , 2014, FEBS letters.
[18] T. Yoshimine,et al. Wilms' tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis. , 2014, Anticancer research.
[19] J. Xu,et al. WT1 Promotes Cell Proliferation in Non-Small Cell Lung Cancer Cell Lines through Up-Regulating Cyclin D1 and p-pRb In Vitro and In Vivo , 2013, PloS one.
[20] Lorne A. Babiuk,et al. Mechanisms of Action of Adjuvants , 2013, Front. Immunol..
[21] S. Canevari,et al. The value of PAX8 and WT1 molecules in ovarian cancer diagnosis. , 2013, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.
[22] G. Soma,et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. , 2011, Anticancer research.
[23] H. Ueno,et al. Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer , 2011, Journal of immunotherapy.
[24] H. Ueno,et al. Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites. , 2010, Japanese journal of clinical oncology.
[25] P. Greenberg,et al. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909 , 2010, Cancer Immunology, Immunotherapy.
[26] H. Hollema,et al. Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian Cancer , 2010, Clinical & developmental immunology.
[27] A. Magliocco,et al. WT1 Immunoprofiling and Comparison of Malignant Mullerian Mixed Tumors of The Female Genital Tract , 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[28] J. Wolchok,et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. , 2010, Blood.
[29] Y. Takeda,et al. A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination. , 2010, Anticancer research.
[30] J. Sakamoto,et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. , 2009, Anticancer research.
[31] E. Thiel,et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. , 2009, Blood.
[32] J. Hatazawa,et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. , 2008, Journal of neurosurgery.
[33] Jeffrey S Barrett,et al. Shortening the timeline of pediatric phase I trials: the rolling six design. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] K. Rezvani,et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. , 2007, Blood.
[35] W. Broaddus,et al. Wilms tumor 1 expression in malignant gliomas and correlation of +KTS isoforms with p53 status. , 2007, Journal of neurosurgery.
[36] J. Inazawa,et al. Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma , 2007, Virchows Archiv.
[37] T. Shuin,et al. WT1 (Wilms' Tumor 1) Peptide Immunotherapy for Renal Cell Carcinoma , 2007, Microbiology and immunology.
[38] H. Lyerly,et al. Immunotherapeutic targeting of Wilms' tumor protein. , 2007, Current opinion in molecular therapeutics.
[39] J. Sakamoto,et al. Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia. , 2007, International journal of hematology.
[40] J. Sakamoto,et al. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. , 2007, International journal of hematology.
[41] E. Thiel,et al. Vaccination with the WT-1 126-134 Peptide in Patients with Acute Myeloid Leukemia after Allogenic Stem Cell Transplantation. , 2006 .
[42] I. Kawase,et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells , 2006, Modern Pathology.
[43] A. Geater,et al. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study , 2006, BMC Cancer.
[44] J. Hatazawa,et al. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. , 2006, Japanese journal of clinical oncology.
[45] Kunle Odunsi,et al. Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. , 2006, Gynecologic Oncology.
[46] K. Tabuchi,et al. Expression of the Wilms' tumor gene product WT1 in glioblastomas and medulloblastomas , 2006, Brain Tumor Pathology.
[47] H. Sugiyama. Cancer immunotherapy targeting Wilms’ tumor gene WT1 product , 2005, Expert review of vaccines.
[48] M. Waldstrøm,et al. Immunohistochemical expression of wilms tumor gene protein in different histologic subtypes of ovarian carcinomas. , 2005, Archives of pathology & laboratory medicine.
[49] T. Kyo,et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[50] A. Gown,et al. Wilms Tumor Gene Product: Sensitive and Contextually Specific Marker of Serous Carcinomas of Ovarian Surface Epithelial Origin , 2004, Applied immunohistochemistry & molecular morphology : AIMM.
[51] Yoshifumi Yamamoto,et al. Overexpression of the Wilms' tumor gene WT1 in head and neck squamous cell carcinoma , 2003, Cancer Science.
[52] D Middleton,et al. New allele frequency database: http://www.allelefrequencies.net. , 2003, Tissue antigens.
[53] S. Miyoshi,et al. Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers , 2002, International journal of cancer.
[54] E. Bertelmann,et al. Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens , 2000, Journal of Cancer Research and Clinical Oncology.